NEW YORK, Sept. 13, 2024 (GLOBE NEWSWIRE) — PRISM MarketView presents an unique Q&A with Brent Ness, CEO and Director of Aclarion, Inc. (Nasdaq: ACON). As a disruptive healthcare know-how firm targeted on continual low again ache, Aclarion is on the forefront of growing noninvasive instruments to assist physicians determine the supply of ache in spinal discs, probably revolutionizing the usual of take care of this widespread and debilitating situation.
Aclarion’s Nociscan platform, powered by augmented intelligence algorithms and biomarkers, represents a breakthrough in continual ache therapy. With new business agreements, UK payer protection for Nociscan and over $50 million invested within the firm’s AI platform, Aclarion is making vital strides towards standard-of-care standing within the $134 billion U.S. continual low again ache market. The corporate’s know-how is protected by 40 issued patents and 12 pending purposes.
Highlights from the Q&A:
Nociscan’s Vital Function in Medical Trials Ness highlighted Nociscan’s choice within the ongoing LIFEHAB Trial in Norway, a randomized managed examine evaluating therapy outcomes for sufferers with continual low again ache. The trial goals to judge how Nociscan’s magnetic resonance spectroscopy (MRS) biomarkers can help in figuring out optimum therapy choices. “We’re happy with the progress and sit up for seeing the info additional help the usage of Nociscan in predicting therapy success,” Ness stated.
Growth in Analysis and Medical Adoption The dialogue touched on Aclarion’s rising momentum in medical trials and analysis. “We’re awaiting outcomes from a accomplished trial in Rome, and two NIH-funded research within the U.S. inspecting Nociscan’s function in treating low again ache,” Ness shared. Moreover, Aclarion’s CLARITY trial will enroll as much as 300 sufferers throughout eight websites, aiming to validate Nociscan’s potential to enhance surgical outcomes.
KOL Partnerships Driving Payer Protection Aclarion has additionally made vital progress in securing payer protection. “Key Opinion Chief (KOL) surgeons are important in advocating for Nociscan and driving insurance coverage protection selections. We’re working with 10 of the highest spine surgeons globally, who see the medical utility of our know-how,” Ness defined.
Strategic Progress within the U.S. Wanting forward, Aclarion is increasing its partnerships in key markets throughout the U.S., focusing on the non-public injury and employee compensation sectors with its confirmed Nociscan know-how. “We imagine the best prognosis could make a major distinction for employees and insurance coverage suppliers,” Ness acknowledged.
The complete interview with Aclarion’s CEO Brent Ness might be discovered at: PRISM MarketView – Aclarion Q&A : https://prismmarketview.com/disrupting-chronic-pain-treatment-aclarions-nociscan-leads-the-way-in-identifying-painful-spinal-discs/
About Aclarion, Inc.
Aclarion is a healthcare know-how firm that leverages Magnetic Resonance Spectroscopy (“MRS”), proprietary sign processing methods, biomarkers and augmented intelligence algorithms to optimize medical therapies. The Firm is first addressing the continual low again ache market with Nociscan, the primary, evidence-supported, SaaS platform to noninvasively assist physicians distinguish between painful and nonpainful discs within the lumbar spine. By way of a cloud connection, Nociscan receives MRS knowledge from an MRI machine for every lumbar disc being evaluated. Within the cloud, proprietary sign processing methods extract and quantify chemical biomarkers demonstrated to be related to disc ache. Biomarker knowledge is entered into proprietary algorithms to point if a disc could also be a supply of ache. When used with different diagnostic instruments, Nociscan gives important insights into the situation of a affected person’s low again ache, giving physicians readability to optimize therapy methods. For extra data, please go to www.aclarion.com.
Ahead Wanting Statements
This press launch incorporates forward-looking statements throughout the that means of the Non-public Securities Litigation Reform Act of 1995, Part 27A of the Securities Act of 1933 and Part 21E of the Securities Change Act of 1934 concerning the Firm’s present expectations about future outcomes, efficiency, prospects and alternatives. Statements that aren’t historic details, akin to “anticipates,” “believes” and “expects” or comparable expressions, are forward-looking statements. These forward-looking statements are based mostly on the present plans and expectations of administration and are topic to numerous uncertainties and dangers that would considerably have an effect on the Firm’s present plans and expectations, in addition to future outcomes of operations and monetary situation. These and different dangers and uncertainties are mentioned extra absolutely in our filings with the Securities and Change Fee. Readers are inspired to assessment the part titled “Threat Components” within the Firm’s Annual Report on Type 10-Okay for the 12 months ended December 31, 2023, in addition to different disclosures contained within the Prospectus and subsequent filings made with the Securities and Change Fee. Ahead-looking statements contained on this announcement are made as of this date and the Firm undertakes no obligation to publicly replace or revise any forward-looking statements, whether or not on account of new data, future occasions or in any other case.
About PRISM MarketView:
Established in 2020, PRISM MarketView is devoted to the monitoring and evaluation of small cap shares in burgeoning sectors. We ship up-to-the-minute monetary market information, present complete investor instruments and foster a dynamic investor neighborhood. Central to our choices are proprietary indexes that observe rising sectors, together with biotech, clear power, next-generation tech, medical units and past. Go to us at prismmarketview.com and comply with us on Twitter.
PRISM MarketView doesn’t present funding recommendation.
Disclaimer
This communication was produced by PRISM MarketView, an affiliate of PCG Advisory Inc., (collectively “PCG”). PCG isn’t a registered or licensed broker-dealer nor funding adviser. No data contained on this communication constitutes a suggestion to promote, a solicitation of a suggestion to purchase, or a suggestion of any safety. PCG could also be compensated by respective purchasers for publicizing data referring to its purchasers’ securities. See www.pcgadvisory.com/disclosures.
Contact:
PRISM MarketView
information@prismmarketview.com
646-863-6341
Pictures accompanying this announcement can be found at
https://www.globenewswire.com/NewsRoom/AttachmentNg/379e573f-4988-4b42-8d56-83cb74c3dd07
https://www.globenewswire.com/NewsRoom/AttachmentNg/e3ca42bd-4fbe-4a22-988d-5d6936e3c91f
Discussion about this post